Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
One of the first projects to be selected for funding under the European Innovative Medicines Initiative will address the challenges of developing drugs to treat schizophrenia and depression.
The successful reprogramming of adult cells into induced pluripotent stem (iPS) cells without viral vectors adds to the excitement about the application of iPS cells in drug discovery and development.
With US$1.1 billion now allocated for comparative effectiveness research in the United States, a key question is how to use this opportunity to develop a better model for the assessment of health-care value.
Biopharmaceutical and generic companies alike are investing in the follow-on biologics space in advance of patent expirations of major therapeutic protein products from 2013 onwards.